Multimodality molecular imaging of glioblastoma growth inhibition with vasculature-targeting fusion toxin VEGF121/rGel

Journal of Nuclear Medicine

Volumn 48, Issue 3, 2007, Pages 445-454

  Hsu, Andrew R ^a   Cai, Weibo ^a   Veeravagu, Anand ^b   Mohamedali, Khalid A ^c   Chen, Kai ^a   Kim, Sehoon ^c   Vogel, Hannes ^b   Hou, Lewis C ^b   Tse, Victor ^b   Rosenblum, Michael G ^c   Chen, Xiaoyuan ^a  

^a STANFORD UNIVERSITY   (United States)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Angiogenesis; Gelonin; Glioblastoma multiforme; VEGF121; VEGFR 2 (Flk 1 KDR)

Indexed keywords

1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID; GELONIN; VASCULOTROPIN 121; 2',3' DIDEOXYNUCLEOSIDE DERIVATIVE; 3' FLUOROTHYMIDINE; COPPER; DIAGNOSTIC AGENT; GEL PROTEIN, GELONIUM MULTIFLORUM; HYBRID PROTEIN; UNCLASSIFIED DRUG; VASCULAR ENDOTHELIAL GROWTH FACTOR A, HUMAN; VASCULOTROPIN A; VASCULOTROPIN RECEPTOR; VEGETABLE PROTEIN;

ANIMAL MODEL; ARTICLE; BIOLUMINESCENCE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; GLIOBLASTOMA; GROWTH INHIBITION; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; MOLECULAR IMAGING; MOUSE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; TUMOR GROWTH; TUMOR VOLUME; VASCULARIZATION; ANIMAL; BLOOD BRAIN BARRIER; METABOLISM; POSITRON EMISSION TOMOGRAPHY;

ANIMALS; BLOOD-BRAIN BARRIER; COPPER RADIOISOTOPES; DIDEOXYNUCLEOSIDES; GLIOBLASTOMA; MAGNETIC RESONANCE IMAGING; MICE; PLANT PROTEINS; POSITRON-EMISSION TOMOGRAPHY; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; RECOMBINANT FUSION PROTEINS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 34247208168     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Black PM. Brain tumor. Part 2. N Engl J Med. 1991;324:1555-1564.
2. Deen DF, Chiarodo A, Grimm EA, et al. Brain Tumor Working Group Report on the 9th International Conference on Brain Tumor Research and Therapy. Organ System Program, National Cancer Institute. J Neurooncol. 1993;16:243-272.
3. 3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels. Cell. 1994;79:1157-1164.
4. Furumatsu T, Nishida K, Kawai A, Namba M, Inoue H, Ninomiya Y. Human chondrosarcoma secretes vascular endothelial growth factor to induce tumor angiogenesis and stores basic fibroblast growth factor for regulation of its own growth. Int J Cancer. 2002;97:313-322.
5. Bikfalvi A, Bicknell R. Recent advances in angiogenesis, anti-angiogenesis and vascular targeting. Trends Pharmacol Sci. 2002;23:576-582.
6. Kumamoto H, Ohki K, Ooya K. Association between vascular endothelial growth factor (VEGF) expression and tumor angiogenesis in ameloblastomas. J Oral Pathol Med. 2002;31:28-34.
7. Fine BA, Valente PT, Feinstein GI, Dey T. VEGF, flt-1, and KDR/flk-1 as prognostic indicators in endometrial carcinoma. Gynecol Oncol. 2000;76:33-39.
8. 121/rGel inhibits the growth of orthotopic human bladder carcinoma tumors. Neoplasia. 2005;7:912-920.
9. Price DJ, Miralem T, Jiang S, Steinberg R, Avraham H. Role of vascular endothelial growth factor in the stimulation of cellular invasion and signaling of breast cancer cells. Cell Growth Differ. 2001;12:129-135.
10. Itakura J, Ishiwata T, Shen B, Kornmann M, Korc M. Concomitant over-expression of vascular endothelial growth factor and its receptors in pancreatic cancer. Int J Cancer. 2000;85:27-34.
11. Fischer I, Gagner JP, Law M, Newcomb EW, Zagzag D. Angiogenesis in gliomas: biology and molecular pathophysiology. Brain Pathol. 2005;15:297-310.
12. Senger DR, Van de Water L, Brown LF, et al. Vascular permeability factor (VPF, VEGF) in tumor biology. Cancer Metastasis Rev. 1993;12:303-324.
13. Brekken RA, Overholser JP, Stastny VA, Waltenberger J, Minna JD, Thorpe PE. Selective inhibition of vascular endothelial growth factor (VEGF) receptor 2 (KDR/Flk-1) activity by a monoclonal anti-VEGF antibody blocks tumor growth in mice. Cancer Res. 2000;60:5117-5124.
14. Fabbro D, Ruetz S, Bodis S, et al. PKC412: a protein kinase inhibitor with a broad therapeutic potential. Anticancer Drug Des. 2000;15:17-28.
15. 121/rGelonin chimeric fusion toxin targeting the neovasculature of solid tumors. Proc Natl Acad Sci U S A. 2002;99:7866-7871.
16. Akiyama H, Mohamedali KA, e Silva RL, et al. Vascular targeting of ocular neovascularization with a vascular endothelial growth factor121/gelonin chimeric protein. Mol Pharmacol. 2005;68:1543-1550.
17. 121/rGel inhibits pulmonary metastases of MDA-MB-231 breast tumors. Neoplasia. 2005;7:486-496.
18. Eggert A, Ikegaki N, Kwiatkowski J, Zhao H, Brodeur GM, Himelstein BP. High-level expression of angiogenic factors is associated with advanced tumor stage in human neuroblastomas. Clin Cancer Res. 2000;6:1900-1908.
19. Rasey JS, Grierson JR, Wiens LW, Kolb PD, Schwartz JL. Validation of FLT uptake as a measure of thymidine kinase-1 activity in A549 carcinoma cells. J Nucl Med. 2002;43:1210-1217.
20. 3. Cancer Res. 2006;66:9673-9681.
21. 64Cu-labeled tetrameric RGD peptide. J Nucl Med. 2005;46:1707-1718.
22. Cai W, Chen K, Mohamedali KA, et al. PET of vascular endothelial growth factor receptor expression. J Nucl Med. 2006;47:2048-2056.
23. 3 in an orthotopic glioblastoma model. Mol Imaging Biol. 2006;8:315-323.
24. Schmidt KF, Ziu M, Schmidt NO, et al. Volume reconstruction techniques improve the correlation between histological and in vivo tumor volume measurements in mouse models of human gliomas. J Neurooncol. 2004;68:207-215.
25. 3-targeted imaging of lung cancer. Neoplasia. 2005;7:271-279.
26. 3 in living mice with mutant herpes simplex virus type 1 thymidine kinase PET reporter gene. J Nucl Med. 2006;47:130-139.
27. 18F-labeled RGD peptide. Mol Imaging Biol. 2006;8:9-15.
28. 18F]FDG PET. Eur J Nucl Med. 2001;28:1326-1335.
29. 18F-fluorothymidine microPET studies in tumor xenografts in mice. J Nucl Med. 2005;46:1851-1857.
30. Jekunen A, Kairemo K, Karnani P. In vivo modulators of antibody kinetics. Acta Oncol. 1996;35:267-271.
31. Rijken PF, Peters JP, Van der Kogel AJ. Quantitative analysis of varying profiles of hypoxia in relation to functional vessels in different human glioma xenograft lines. Radiat Res. 2002;157:626-632.
32. Joensuu H, Puputti M, Sihto H, Tynninen O, Nupponen NN. Amplification of genes encoding KIT, PDGFRalpha and VEGFR2 receptor tyrosine kinases is frequent in glioblastoma multiforme. J Pathol. 2005;207:224-231.
33. Schneider SW, Ludwig T, Tatenhorst L, et al. Glioblastoma cells release factors that disrupt blood-brain barrier features. Acta Neuropathol (Berl). 2004;107:272-276.
34. Brown LF, Berse B, Jackman RW, et al. Expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in breast cancer. Hum Pathol. 1995;26:86-91.
35. Ziche M, Donnini S, Morbidelli L. Development of new drugs in angiogenesis. Curr Drug Targets. 2004;5:485-493.
36. 124I]iodinated-VG76e: a novel tracer for imaging vascular endothelial growth factor in vivo using positron emission tomography. Cancer Res. 2002;62:5912-5919.
37. Chan C, Sandhu J, Guha A, et al. A human transferrin-vascular endothelial growth factor (hnTf-VEGF) fusion protein containing an integrated binding site for 111In for imaging tumor angiogenesis. J Nucl Med. 2005;46:1745-1752.
38. Pedley RB, El-Emir E, Flynn AA, et al. Synergy between vascular targeting agents and antibody-directed therapy. Int J Radiat Oncol Biol Phys. 2002;54:1524-1531.
39. Siemann DW, Mercer E, Lepler S, Rojiani AM. Vascular targeting agents enhance chemotherapeutic agent activities in solid tumor therapy. Int J Cancer. 2002;99:1-6.
40. Talpaz M, Kantarjian HM, Freireich EJ, et al. Phase I clinical trial of the anti-CD-33 immunotoxin Hum195/rGel. Paper presented at: 94th Annual Meeting of the American Association for Cancer Research; July 14, 2003; Washington, D.C. Abstract R5362.